About 6 results found for searched term "AKT-IN-17" (0.126 seconds)
Cat.No. | Name | Target |
---|---|---|
M43375 | AKT-IN-17 | Akt |
AKT-IN-17 is a AKt inhibitor. | ||
M1654 | AT7867 | Akt |
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase with an IC50 of 17 nM. | ||
M11229 | Miransertib hydrochloride | Akt |
ARQ-092 hydrochloride | ||
Miransertib hydrochloride (ARQ-092 Hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with an IC50 of 2.7 nM for Akt1, Akt2, and Akt3, respectively. 14 nM and 8.1 nM. Miransertib hydrochloride is an effective inhibitor of AKT1-E17K mutant protein, and can be used in the study of PI3K/ AkT-driven tumors and Proteus syndrome. Miransertib hydrochloride effectively inhibited Leishmania. | ||
M21373 | TAS-117 | Akt |
TAS-117 is a potent, selective, orally active allosteric Akt inhibitor (IC50 of 4.8, 1.6 and 44 nM for Akt1, 2 and 3, respectively).TAS-117 stimulates anti-myeloma activity and enhances lethal endoplasmic reticulum stress induced by proteasome inhibition.TAS-117 induces apoptosis and autophagy. autophagy). | ||
M28377 | Vevorisertib trihydrochloride | Akt |
ARQ 751 trihydrochloride | ||
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. | ||
M30829 | Akt1/Akt2-IN-1 | Akt |
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of Akt1 (IC50=3.5 nM) and Akt2 (IC50=42 nM), with potent and balanced activity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.